Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

• Published in: Journal of clinical oncology Vol. 37; no. 3; pp. 202 - 212
• Main Authors: Sha, Chulin, Barrans, Sharon, Cucco, Francesco, Bentley, Michael A, Care, Matthew A, Cummin, Thomas, Kennedy, Hannah, Thompson, Joe S, Uddin, Rahman, Worrillow, Lisa, Chalkley, Rebecca, van Hoppe, Moniek, Ahmed, Sophia, Maishman, Tom, Caddy, Josh, Schuh, Anna, Mamot, Christoph, Burton, Catherine, Tooze, Reuben, Davies, Andrew, Du, Ming-Qing, Johnson, Peter W M, Westhead, David R
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 20.01.2019
• Subjects: Antibodies, Monoclonal, Murine-Derived - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Bortezomib - administration & dosage; Cyclophosphamide - administration & dosage; Databases, Genetic; Doxorubicin - administration & dosage; Female; Humans; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Middle Aged; Neoplasm Grading; ORIGINAL REPORTS; Prednisone - administration & dosage; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab - administration & dosage; Transcriptome; Vincristine - administration & dosage

Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt lymphoma is well known. Conventional cytogenetics identifies some patients with rearrangements of MYC and BCL2 and/or BCL6 (double-hit...